Practical implication
Manufacturers must verify that their products meet the newly established acceptable intake levels for nitrosamines and implement necessary quality control measures to keep impurities within limits.
EMA updated the acceptable intake levels for nitrosamine impurities in human medicines, establishing new limits that manufacturers must comply with to control these impurities.
What changed: EMA released an update to Appendix 1 of the nitrosamines referral, setting revised acceptable intake limits for nitrosamine impurities in human medicinal products.
Why it matters: Nitrosamine impurities are potential carcinogens; updated limits ensure patient safety and require manufacturers to reassess and control impurity levels in their products.
Practical implication: Manufacturers must verify that their products meet the newly established acceptable intake levels for nitrosamines and implement necessary quality control measures to keep impurities within limits.
View original source
Published from the Firecrawl agent regulatory extraction pipeline.
